Urological implications of cyclophosphamide and ifosfamide.
about
Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective.A cultured approach to canine urothelial carcinoma: molecular characterization of five cell linesSystemic treatment in breast cancer: a primer for radiologistsCyclophosphamide-induced Hepatotoxicity in Wistar Rats: The Modulatory Role of Gallic Acid as a Hepatoprotective and Chemopreventive PhytochemicalThe glycine deportation system and its pharmacological consequences.Complications of oncologic therapy in the abdomen and pelvis: a review.Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation.Cyclophosphamide in dermatology.Gamma-Glutamylcysteine Ethyl Ester Protects against Cyclophosphamide-Induced Liver Injury and Hematologic Alterations via Upregulation of PPARγ and Attenuation of Oxidative Stress, Inflammation, and Apoptosis.The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study.Evaluation of the anti-inflammatory and urotoxicity ameliorative effects of γ-humulene containing active fraction of Emilia sonchifolia (L.) DC.Pretreatment with melatonin protects against cyclophosphamide-induced oxidative stress and renal damage in mice.Urinary uroplakin expression in cyclophosphamide-induced rat cystitis model.Therapeutic exploitation of IPSE, a urogenital parasite-derived host modulatory protein, for chemotherapy-induced hemorrhagic cystitis.Effects of the hydroalcoholic extract of Phyllanthus niruri and its isolated compounds on cyclophosphamide-induced hemorrhagic cystitis in mouse
P2860
Q30405427-63B222C5-DD86-4723-BFA1-D640F422884DQ36084359-A64B188D-86D4-4583-9EB9-3BFCDF6A2421Q36510679-49C69F8A-7162-4FA6-8F0B-AD8C26B8A224Q36733032-7A010C90-4B3E-4880-8D16-29D56FF00976Q36880287-69764869-009B-4C36-B83B-895260E5B1A6Q38014349-9508C497-5AAA-4F0F-B2BD-94A56D4E9653Q38068541-4584AC32-5D66-4DF0-81E8-8CE796A89A75Q38710150-D0FF14E8-169B-4E8E-BF18-79C47B4915EBQ39028144-C9356AEF-6FC2-44B5-927F-2356F29C6604Q42154761-78AF8DBA-CA82-4FAA-98DF-D34617C25264Q47311380-1BF516F9-35C9-48CC-8B2D-4158346C6311Q48152261-740C2F0E-193B-4399-810C-DC5D7CCFAF19Q50977201-4CE8F5C2-F9FD-4FEF-B9D0-DC3098C6A1DBQ52610360-FA89AE61-DA99-4E98-B5D6-356849AAFEBEQ58310862-190295AA-5EE5-442F-A644-A670033DB9CD
P2860
Urological implications of cyclophosphamide and ifosfamide.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Urological implications of cyclophosphamide and ifosfamide.
@en
Urological implications of cyclophosphamide and ifosfamide.
@nl
type
label
Urological implications of cyclophosphamide and ifosfamide.
@en
Urological implications of cyclophosphamide and ifosfamide.
@nl
prefLabel
Urological implications of cyclophosphamide and ifosfamide.
@en
Urological implications of cyclophosphamide and ifosfamide.
@nl
P2093
P2860
P1476
Urological implications of cyclophosphamide and ifosfamide.
@en
P2093
Annamarie De Vries
Arthur Vasilaras
David Nicol
Malcolm Lawson
Peter Mactaggart
P2860
P304
P356
10.1080/00365590701570953
P577
2008-01-01T00:00:00Z